AK MEDICAL HOLDINGS LIMITED
愛康醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1789)

VOLUNTARY ANNOUNCEMENT

INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

This announcement is made by AK Medical Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis. Reference is made to the announcement of the Company dated 2 February 2026 in relation to the proposed on-market share repurchase by the Company pursuant to the Share Repurchase Mandate (as defined below) up to HK$150,000,000.

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders (the "**Shareholders**") and potential investors of the Company that the Board have an intention to exercise their powers under the general mandate (the "**Share Repurchase Mandate**") granted to the Directors pursuant to the resolutions of the Shareholders passed at the annual general meeting held on 18 June 2025 (the "**2025 AGM**"), to repurchase shares of the Company (the "**Shares**") not exceeding 10% of the total number of the issued Shares as at the date of the 2025 AGM, namely, up to 112,269,577 Shares. The Share Repurchase Mandate will remain in effect until the earliest of (i) the conclusion of the first annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held by the articles of association (the "**Articles of Association**") or any applicable laws; and (iii) the date on which such authority is revoked or varied by an ordinary resolution of the Shareholders in a general meeting of the Company. Details of the Shares Repurchase Mandate are set out in the circular of the Company dated 25 April 2025.

The Directors have resolved to utilize the Share Repurchase Mandate and subject to market conditions use up to HK$500,000,000 (increased from the original budget of HK$150,000,000) to conduct the proposed share repurchase in the open market on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") from time to time (the "**Proposed Share Repurchase**") up to the date of expiry of the Share Repurchase Mandate, namely, 17 June 2026, being the date of the forthcoming annual general meeting. The Company intends to finance the Proposed Share Repurchase by its internal financial resources. The Company intends to hold all of the repurchased Shares repurchased pursuant to the Share Repurchase Mandate as treasury shares (instead of cancellation) following settlement in accordance with applicable rules and regulations. As of Friday, 5 June 2026, the Company has utilized the Share Repurchase Mandate to repurchase 14,462,000 Shares for an aggregate consideration of approximately HK$87,652,260.

The Company will conduct the Proposed Share Repurchase in compliance with the Articles of Association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Act of the Cayman Islands and all applicable laws and regulations to which the Company is subject to. The Board will continue to monitor the market conditions and will repurchase Shares in the open market on the Stock Exchange at appropriate times in accordance with the requirements under Rule 10.06 of the Listing Rules. The Proposed Share Repurchase will not result in the number of the Shares held by the public falling below the relevant minimum percentage prescribed by the Listing Rules.

The Board believes that the Proposed Share Repurchase demonstrates the confidence of Board in the business outlook and prospects of the Group and will create value to the Shareholders. The Board believes that the current internal financial resources of the Company would enable it to implement the Proposed Share Repurchase while maintaining a solid financial position.

Shareholders and potential investors should note that any repurchase of Shares may be conducted subject to market conditions and at the absolute discretion of the Board. There is no assurance of the timing, quantity or price of any repurchase of Shares. Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

By order of the Board
AK Medical Holdings Limited
Li Zhijiang
Chairman

Hong Kong, 7 June 2026

As at the date of this announcement, the Board comprises Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong as executive Directors, Dr. Wang David Guowei as non-executive Director, and Mr. Kong Chi Mo, Dr. Li Shu Wing David and Dr. Gao Wei as independent non-executive Directors.